Territory Stories

NT trends in ecstasy and related drug markets 2011 : findings from the Ecstasy and Related Drugs Reporting System (EDRS)

Details:

Title

NT trends in ecstasy and related drug markets 2011 : findings from the Ecstasy and Related Drugs Reporting System (EDRS)

Collection

NT trends in ecstasy and related drug markets; Reports; PublicationNT

Date

2011

Description

Made available via the Publications (Legal Deposit) Act 2004 (NT).

Notes

Date:2011; Australian drug trends series No. 80

Language

English

Subject

Drug abuse surveys -- Northern Territory -- Periodicals; Ecstasy (Drug) -- Northern Territory -- Periodicals; Drug abuse -- Northern Territory -- Periodicals

Publisher name

National Drug and Alcohol Research Centre, University of New South Wales

Place of publication

Sydney (N.S.W)

ISBN

9780733430206

Copyright owner

Check within Publication or with content Publisher.

Parent handle

https://hdl.handle.net/10070/242182

Citation address

https://hdl.handle.net/10070/610318

Page content

9 Figure 2 shows the decrease in morphine as the drug injected most often in the previous month while also illustrating an increase in methamphetamine use (18% compared to 6% in 2010). Four percent of the sample identified heroin as the drug injected most often in the previous month whereas none did so in 2010. Figure 2: Drug injected most last month, 2002-2011 Source: IDRS participant interviews Polydrug use histories and routes of administration are shown in Table 3. As in 2010 the most commonly used illicit drug in 2011 was non-prescribed morphine although the 72% who reported use in the past six months represents a significantly lower proportion than the 89% who reported recent use in 2010. At 71%, cannabis was again the next most commonly used illicit drug, and the proportion of the sample who reported recent use was almost identical to the 2010 result (72%). Illicit morphine remained the main drug most recently injected (69%) but again this is a sizeable reduction from the 89% reported in 2010, as well as from 81% in 2009 and 84% in 2008. Illicit morphine continued to be the most common drug ever injected (79%), followed by heroin (73%) and speed powder (72%). Recent use of methamphetamine in any form increased to 55% of the sample (36% in 2010), mirroring the 2009 result. Reported recent intravenous use of any form of methamphetamine increased from 34% in 2010 to 51% in 2011. There was also an increase in reported smoking of ice, from 3% of the sample in 2010 to 13% in 2011. In 2011 reported recent use of base methamphetamine doubled from 2010 to 12%, but this remained lower than the 16% who reported recent use in 2009. Recent use of methamphetamine liquid remained low at 4% of the sample (2% in 2010). In 2011 recent reported use of heroin almost doubled from the 2010 result to 9% of the sample but this remained lower than the 13% who reported recent use in 2009 and 14% who reported recent use in 2008. There was again considerable variation in reported recent use of illicit pharmaceutical opioids. As in 2010, recent use of illicit Physeptone was most common (27% in 2011, 26% in 2010 and 22% in 2009), followed by illicit oxycodone (26% in 2011, 22% in 2010 and 35% in 2009). Reported recent use of illicit buprenorphine-naloxone (Suboxone) at 14% of the sample was similar to that reported in 2010 (15% in 2010 and 8% in 2009). Recent use of illicit methadone syrup was 11%, identical to the 2010 result (15% in 2009.) At 8% of the sample, recent use of illicit buprenorphine (Subutex) was also identical to the 2010 result (5% in 2009). 0 10 20 30 40 50 60 70 80 90 2002 2003 2004 2005 2006 2007 2008 2009 2010 2011 P e rc e n ta ge Heroin Methamphetamine Morphine


Aboriginal and Torres Strait Islander people are advised that this website may contain the names, voices and images of people who have died, as well as other culturally sensitive content. Please be aware that some collection items may use outdated phrases or words which reflect the attitude of the creator at the time, and are now considered offensive.

We use temporary cookies on this site to provide functionality.
By continuing to use this site without changing your settings, you consent to our use of cookies.